-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, China Biopharmaceutical (01177.HK) issued an announcement. The final results of the Phase I clinical study of the national Class 1 innovative drug Kylo-11 “LPA siRNA” independently developed by Hangzhou Hejia Biomedical Co., Ltd. (“Hegia Biology”), a wholly-owned subsidiary of the Group, were released in the 2026 European Society of Cardiology Annual Meeting (ESC) in the form of an oral report; at the same time, the full study was published in the top international medical journal “Liu “Leaf Knives” (The Lancet, IF: 109).

Zhitongcaijing·08/31/2026 00:25:04
Listen to the news
Zhitong Financial App News, China Biopharmaceutical (01177.HK) issued an announcement. The final results of the Phase I clinical study of the national Class 1 innovative drug Kylo-11 “LPA siRNA” independently developed by Hangzhou Hejia Biomedical Co., Ltd. (“Hegia Biology”), a wholly-owned subsidiary of the Group, were released in the 2026 European Society of Cardiology Annual Meeting (ESC) in the form of an oral report; at the same time, the full study was published in the top international medical journal “Liu “Leaf Knives” (The Lancet, IF: 109).